Objective: To determine the association between p53 expression and the probability of organ confinement in patients with prostate cancer in Sardjito Hospital, Yogyakarta. Material & method: Prostate specimens were obtained from patients with clinical stage T1-T2 prostatic adenocarcinoma in Sardjito Hospital between January 2007 and December 2008. Samples were processed and immunohistochemically stained in the Department of Anatomical Pathology Gadjah Mada University. Probability of organ confinement was determined by updated Partin table 2007 from preoperative serum PSA level, Gleason Score, and clinical stage. Correlation between p53 expression and probability of organ confinement were statistically analyzed by Spearman correlation test. Results: There were 28 prostate cancer patients eligible for this study. Mean age was 65,19 ± 10,9 (28 - 81) years old. Mean preoperative PSA level were 107,13 ± 165,82 (0,20 734,20) ng/ml. Mean number of p53 expression was 97,47 ± 97,27 (5 - 396)/HPF. Significant correlation was found between p53 expression and probability of organ confinement (Spearman r = -0,441; p = 0,019). Conclusion: p53 expression was negatively correlated with the level of organ confinement in patients with prostate cancer
Makarov D, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin Tables), based on cases from 2000 to 2005. Urology 2007; 69: 1095-101.
Papadopoulos I, Rudolph P, Wirth B, Weichert- Jacobsen K. P53 expression, proliferation marker Ki-
, DNA content and serum PSA: Possible biopotential markers in human prostatic cancer. Urology 1996; 48:
Heidenberg HB, Bauer JJ, McLeod DG, Moul MJ, Srivastava S. The role of the p53 tumor suppressor gene in prostate cancer: A possible biomarker? Urology 1996; 48: 927-8
Shurbaji MS, John H, Kalbfleisch, Thurmond TS.
Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol; 26: 106-9
Matsushima H, Sasaki T, Goto T, Hosaka Y, Homma Y, Kitamura T, et al. Immunohisto-chemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance. Hum Pathol 1998; 29: 778-83
Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer
; 41: 858-87.
Downing SR, Jackson P, Russell PJ. Mutations within the tumor suppressor gene p53 are not confined to a late event in prostate cancer progression: A review of the evidence. Urol Oncol 2001; 6: 103-10
Slavov C, Vlahova A, Christova S, Popov E.
Expression of Ki67, p21, p53 in prostate biopsy tissue. Urology 2006; 68 (Suppl 5A).
Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Expression of potential molecular markers in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Seminars and Original Investigations. Urol Oncol; 2008